Group 1: A-Share Buyback Events - During the period from February 23, 2026, to March 1, 2026, a total of 6 listed companies announced shareholder buyback plans, with the average buyback amount as a percentage of total market capitalization being 0.18% for Aidi Pharmaceutical, 1.09% for Binhua Co., 0.04% for Tongce Medical, 0.07% for Huaneng Hydropower, 1.69% for Biyinlefen, and 0.80% for Conch Cement [1][8][11]. Group 2: Key Companies of Interest - **Biyinlefen**: The company announced its first buyback and the controlling shareholder plans to buy back more than 1% of shares, with an amount between 100 million and 200 million RMB, reflecting confidence in the company's long-term prospects as a leading high-end apparel group focused on golf lifestyle [2][13]. - **Aidi Pharmaceutical**: The controlling shareholder plans to buy back 0.18% of shares, with an expected turnaround from loss to profit and a high growth rate in net profit forecasted [2][14][15]. - **Conch Cement**: The controlling shareholder plans to buy back 0.80% of shares, with a buyback amount between 7 billion and 14 billion RMB, indicating recognition of the company's long-term value in the cement industry [3][20][21]. Group 3: Management Buyback Announcements - From February 23, 2026, to March 1, 2026, 9 listed companies announced management buyback plans, with the only company exceeding 0.01% of total market capitalization being Sruy New Materials [11].

Core Viewpoint - Eddie Pharmaceuticals reported a significant revenue increase of 72.49% in 2025, driven by rising income from innovative anti-HIV drugs and operational data from its subsidiary, Nanda Pharmaceuticals. The company's losses narrowed from 141 million yuan in 2024 to 19.73 million yuan in 2025, marking an 86.02% reduction in loss margin [1][2]. Group 1: Financial Performance - The company achieved a revenue of 721 million yuan in 2025, with a year-on-year growth of 72.49% [2]. - The loss for 2025 was reduced to 19.73 million yuan from 141 million yuan in 2024, indicating a significant improvement in financial health [2]. - Eddie Pharmaceuticals turned a profit in operating income for the first time, reporting 47.74 million yuan in 2025 [2]. Group 2: Anti-HIV Drug Segment - Revenue from innovative anti-HIV drugs is projected to reach 285 million yuan in 2025, representing a 90.34% increase year-on-year [3]. - The anti-HIV drugs are expected to account for 39.53% of the company's total revenue in 2025 [3]. - The sales of anti-HIV new drugs nearly doubled from 150 million yuan in 2024 to 285 million yuan in 2025 [3]. Group 3: Nanda Pharmaceuticals Contribution - Nanda Pharmaceuticals, a subsidiary, is expected to generate 300 million yuan in revenue for 2025, reflecting a 227.38% increase year-on-year [4]. - Eddie Pharmaceuticals has made several acquisitions to increase its stake in Nanda Pharmaceuticals, enhancing its control and management efficiency [4][6]. - The strategic focus on Nanda Pharmaceuticals aims to solidify Eddie Pharmaceuticals' position in the human protein sector, particularly in the production of urokinase and other biopharmaceuticals [5][6].

Core Viewpoint - Jiangsu Aidi Pharmaceutical (688488.SH) announced a plan to acquire minority shareholder equity in its subsidiary, Nanjing Nanda Pharmaceutical, which will increase its direct shareholding from 51.13% to 73.36% [1][3] Group 1: Acquisition Details - Aidi Pharmaceutical plans to raise up to 185 million yuan through a simplified procedure to fund the acquisition, with 130 million yuan allocated for acquiring 22.23% of Nanda Pharmaceutical's equity and 55 million yuan for working capital [1] - The acquisition is expected to enhance Aidi's control over Nanda Pharmaceutical and optimize financial performance, maximizing synergies between the two companies [4][10] Group 2: Market Potential - The demand for stroke treatment is anticipated to surge, with acute ischemic stroke cases in China projected to rise from 4.1 million in 2023 to 4.9 million by 2027 [4] - The market for neuroprotective drugs in China is expected to grow from 11.5 billion yuan in 2024 to 16.9 billion yuan by 2030, and further to 26.2 billion yuan by 2035 [4] Group 3: Product Pipeline - Aidi's new drugs, AD108 injection and ADB116 injection, are positioned to become significant profit growth drivers, targeting acute ischemic stroke treatment [4] - Aidi's HIV drug, Enomirac, has shown strong sales potential, with revenue from HIV drugs reaching 211 million yuan in the first three quarters of 2025, a 57.12% increase year-on-year [6][7] Group 4: International Expansion - Aidi Pharmaceutical is accelerating its international market expansion, with its HIV drug Enomirac approved for sale in Zanzibar, marking a significant milestone for Chinese-developed HIV drugs in Africa [9] - The company is also advancing its pipeline of innovative drugs, including a new HIV integrase inhibitor and long-acting pre-exposure prophylaxis drugs, which are in various stages of clinical trials [10]

Core Viewpoint - Jiangsu Aidi Pharmaceutical Group Co., Ltd. has successfully renewed the inclusion of two innovative HIV drugs, Ainovelin Tablets and Ainomir Tablets, in the National Medical Insurance Directory for 2025, reflecting the recognition of their clinical value and innovation by the National Healthcare Security Administration [1][5]. Drug Information - **Ainovelin Tablets**: - Drug Name: Ainovelin Tablets - Medical Insurance Payment Standard: 24.15 yuan per tablet - Composition: Ainovelin 0.15g, Lamivudine 0.3g, Tenofovir Disoproxil Fumarate 0.3g - Registration Category: Class 1 chemical drug - Drug Classification: Antiviral drug for HIV infection - Insurance Category: Category B - Dosage Form: Tablet - Exclusive Variety: Yes - Limited Payment Scope: For HIV infection only - Agreement Validity: January 1, 2026, to December 31, 2027 [1][5]. - **Ainomir Tablets**: - Drug Name: Ainomir Tablets - Registration Category: Class 1 chemical drug - Drug Classification: Antiviral drug for HIV infection - Insurance Category: Category B - Dosage Form: Tablet - Exclusive Variety: Yes - Limited Payment Scope: For HIV infection only - Agreement Validity: January 1, 2026, to December 31, 2027 [1][3]. Clinical Efficacy - **Ainovelin Tablets**: - A novel non-nucleoside reverse transcriptase inhibitor (NNRTI) approved in June 2021 for treatment of HIV-1 infection in treatment-naive patients. Phase III clinical trials showed comparable antiviral efficacy to the control drug Efavirenz, with significantly reduced central nervous system side effects and low rates of liver toxicity and rash [2]. - **Ainomir Tablets**: - A compound formulation that includes two nucleoside reverse transcriptase inhibitors (NRTIs) added to Ainovelin. Approved for domestic sale in December 2022, it has shown sustained viral suppression and comparable safety to imported drugs in head-to-head Phase III trials. The drug has demonstrated advantages in cardiovascular metabolic safety indicators [3][4]. Impact on the Company - The renewal of the two innovative HIV drugs in the National Medical Insurance Directory is expected to enhance their sales and market promotion, significantly benefiting the company's operational development. The company aims to establish a marketing system for domestic HIV innovative drugs and provide diverse treatment options for patients, addressing the urgent need for upgraded HIV treatment in China [5].

Group 1 - Heng Rui Pharmaceutical has 9 drugs included in the national medical insurance directory for the first time, with an estimated total sales of approximately 8.66 billion yuan for 2024 and 7.55 billion yuan for the first three quarters of 2025 [5] - Junshi Biosciences' products Tuoyi® and Junshida® have been added to the national medical insurance directory, enhancing patient affordability and market promotion [6] - Huadong Medicine's subsidiary has products included in the national medical insurance and commercial insurance innovative drug directories, expected to aid in market promotion [7] Group 2 - Aidi Pharmaceutical's two innovative HIV drugs have successfully renewed their inclusion in the national medical insurance directory, with specific reimbursement prices set [8] - Fuxing Pharmaceutical has multiple products newly included in the national medical insurance directory, which is anticipated to positively impact future performance [9] - Weichuang Biotechnology's product has been included in the national medical insurance directory, which is expected to enhance market promotion and sales [10] Group 3 - Muxi Co., Ltd. announced a final online issuance rate of 0.03348913% after the mechanism was activated, with a total of 22.83 million shares issued [2] - Doushan New Materials reached a consensus on production reduction in the BOPET industry, although the sustainability of long-term price increases remains uncertain [2] - Guanglian Aviation's controlling shareholder has had the detention lifted, allowing normal operations to resume [3] Group 4 - Jiangjian Co., Ltd. clarified that it bears no obligations for any overdue financial products related to its controlling shareholder, confirming normal operations [4] - Tian Ci Materials' controlling shareholder has committed not to reduce holdings, holding 34.35% of the shares [13] - Annie Co., Ltd. is planning a change in control, with stock resuming trading on December 8 [14]

Core Insights - The innovation drug industry in China is experiencing significant advancements in product research and development, with companies actively discussing their progress and strategies during the recent performance briefing session [1][2][3]. Group 1: Product Innovation and R&D Progress - Companies like Fudan Zhangjiang and Olin Bio are making notable advancements in their product pipelines, focusing on photodynamic therapy and vaccines for "super bacteria" [1][2]. - Fudan Zhangjiang is developing several drugs targeting conditions such as severe acne and bladder cancer, with ongoing clinical studies [2]. - Olin Bio is researching multiple vaccines for "super bacteria," aiming to initiate clinical trials for flu vaccines by mid-2025 [2]. Group 2: Business Expansion and Market Strategy - Companies are planning to expand their production capacity to support product commercialization, with Baiyao Tai focusing on launching several products that have completed Phase III clinical trials [3][4]. - Shian Bio is set to contribute significant revenue from its various vaccine products, including those for swine fever and other diseases [4]. Group 3: Internationalization and Market Entry - The trend of "going global" is a major focus for the domestic biopharmaceutical industry, with companies exploring diverse international pathways [5]. - Yuantong Bio is awaiting FDA approval for its naloxone nasal spray, marking a step towards international market entry [5]. - Aidi Pharmaceutical has received regulatory approval for its HIV treatment in Zanzibar, highlighting its international expansion efforts [6]. - Companies like Ailis and Haichuang Pharmaceutical are actively pursuing overseas partnerships and clinical trials to enhance their global presence [6][7].

Core Insights - Eddie Pharmaceutical experienced a 5.1% increase in stock price, reaching 17.52 CNY per share, with a trading volume of 196 million CNY and a turnover rate of 2.77%, resulting in a total market capitalization of 7.372 billion CNY [1] Company Overview - Jiangsu Eddie Pharmaceutical Group Co., Ltd. was established on December 15, 2009, and went public on July 20, 2020. The company focuses on the exploration, research, and sales of innovative chemical drugs and human-derived protein products [1] - The main revenue sources include: - HIV new drug (Ainomi tablet) 31.96% - Drug (urokinase injection) 19.16% - Senna leaf granules 13.25% - Ustikin crude product 12.08% - Urokinase crude product 10.81% - Other human-derived protein crude products 4.18% - HIV new drug (Ainovelin tablet) 3.92% - Other drugs 2.76% - HIV diagnostic reagents 0.80% - Bacillus cereus tablets 0.54% - Other (supplement) 0.54% [1] Shareholder Insights - Among the top circulating shareholders of Eddie Pharmaceutical, one fund from GF Fund Management, the GF Value Core Mixed A (010377), entered the top ten in the second quarter, holding 3.931 million shares, which is 0.93% of the circulating shares. The estimated floating profit today is approximately 3.3413 million CNY [2] - The GF Value Core Mixed A fund was established on January 22, 2021, with a current scale of 3.516 billion CNY. Year-to-date returns are 64.01%, ranking 307 out of 8180 in its category; the one-year return is 107.77%, ranking 276 out of 7967; since inception, it has a loss of 3.45% [2]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - In H1 2025, the company achieved revenue of 362 million yuan, representing a year-on-year increase of 100.19%, and a net profit of 9 million yuan, up 120.23% year-on-year, marking a turnaround to profitability [4] - The gross margin for H1 2025 was 65.58%, an increase of 16.83 percentage points, while the net margin was 7.31%, up 32.40 percentage points [4] - The company is well-positioned in the HIV treatment and prevention market, with significant growth expected from its innovative drugs [5] Financial Summary - Revenue projections for 2025-2027 are 737 million, 1.037 billion, and 1.237 billion yuan respectively, with net profit forecasts of -2 million, 44 million, and 88 million yuan [4][7] - The company's P/S ratios for the next three years are projected at 10.2, 7.2, and 6.1 times [4][7] - The company reported a sales expense ratio of 34.32% and a management expense ratio of 12.19% in H1 2025 [4] Business Segments - The revenue from human-derived protein crude products was 149 million yuan, while revenue from HIV drugs was 129 million yuan, reflecting a 58.49% increase [4] - The company has a comprehensive HIV research pipeline, with promising results from clinical trials of its drug ACC017 [5]

Core Viewpoint - The HIV drug market in China is experiencing rapid growth due to an increasing number of patients, expanding insurance coverage, and rising payment capabilities among the affected population, with a projected market size of 5.836 billion yuan in 2024, reflecting a year-on-year growth of 30.2% [1][16]. Industry Overview - HIV drugs are antiviral medications aimed at treating AIDS, which is caused by the human immunodeficiency virus (HIV) that attacks the immune system [2]. - As of the end of 2024, there are approximately 1.355 million reported living HIV/AIDS patients in China, with 749,800 being HIV-infected and 605,200 being AIDS patients [1][4]. Market Dynamics - The Chinese HIV drug market is expected to maintain a growth rate of over 20% from 2021 to 2024, driven by the increasing number of patients and the expansion of medical insurance coverage [16]. - The self-paid drug market is projected to reach 3.787 billion yuan in 2024, growing by 47.5% year-on-year, while the free drug market is expected to be 2.049 billion yuan, with a growth of 7% [18]. Competitive Landscape - Gilead and GSK dominate the Chinese HIV drug market, holding a combined market share of 90%, while local companies like Frontier Biopharma and Aidi Pharmaceutical have a smaller market presence of less than 10% [22]. Development Trends - Future research in the global HIV drug market will focus on developing new drugs with better efficacy and safety, exploring new drug targets, and investigating new treatment methods such as gene therapy and immunotherapy [24].

Core Insights - In 2024, domestic innovative drugs, particularly in the HIV sector, are experiencing new growth opportunities driven by national policy support and market demand recovery [2][3] - The company, Aidi Pharmaceutical, is focused on overcoming key technical barriers in the HIV field and aims to provide safe and effective medication options for domestic patients [2][3] Sales Performance - In 2024, the total sales revenue from HIV new drugs reached approximately 149.9 million yuan, representing a year-on-year growth of 103.73% [3][8] - In the first quarter of 2025, the revenue from HIV new drugs was 62.7 million yuan, showing a year-on-year increase of 75.64%, marking a historical high for a single quarter [2][3] Academic Contributions - The company presented the results of the SPRINT study at the 10th National AIDS Academic Conference, demonstrating the long-term value of its drug, Ainomi [4] - The treatment adherence and viral suppression rates for Ainomi in the continuous treatment group were above 95% over 144 weeks, indicating its safety and effectiveness [4] Research and Development - In 2024, the company invested 107.5 million yuan in R&D, a 27.71% increase year-on-year, accounting for 25.73% of its revenue [5] - The company is advancing its pipeline with various projects, including the ACC017 tablet in Phase II clinical trials and long-acting innovative HIV drugs [5] Strategic Partnerships - The company acquired control of Nanda Pharmaceutical to integrate upstream and downstream resources, enhancing its "HIV new drug + human protein" dual strategy [6] - In 2024, Nanda Pharmaceutical achieved a revenue of 298.6 million yuan and a net profit of 51.5 million yuan, with continued collaboration expected to accelerate clinical trials for new drugs [6] Financial Performance - In 2024, the company reported total revenue of 417.8 million yuan, with a net loss of 141.2 million yuan [8] - In the first quarter of 2025, the company achieved revenue of 197.9 million yuan and a net profit of 1.6 million yuan, indicating a positive start to the year [8]